Orexo AB (SE:ORX)
:ORX
Want to see SE:ORX full AI Analyst Report?
ORX Stock Chart & Stats
kr34.55
kr0.22(1.39%)
At close: 4:00 PM EST
kr34.55
kr0.22(1.39%)
Day’s Range― - ―
52-Week Rangekr17.50 - kr43.40
Previous CloseN/A
Volume4.04K
Average Volume (3M)101.19K
Market Cap
kr722.88M
Enterprise Valuekr340.89M
Total Cash (Recent Filing)kr386.20M
Total Debt (Recent Filing)kr7.00M
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Jul 16, 2026EPS Estimate
-1.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.24
Shares Outstanding35,127,056
10 Day Avg. Volume22,969
30 Day Avg. Volume101,192
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.12
Price to Sales (P/S)40.09
P/FCF Ratio6.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-7.26
Revenue Forecast (FY)kr25.60M
Bulls Say, Bears Say
Bulls Say
Improved Cash GenerationA sustained move to positive operating and free cash flow (~117M TTM) materially improves funding flexibility. Over the next 2–6 months this reduces reliance on external financing, supports R&D and commercial activities, and provides a clearer path to stabilizing operations despite prior losses.
Very Low LeverageExtremely low debt-to-equity (~0.02) materially lowers financial risk and interest burden. This structural strength enhances resilience to revenue volatility, preserves strategic optionality for partnerships or M&A, and supports multi-month operational continuity without urgent refinancing needs.
Niche Specialty Pharma And Digital TherapeuticsA focused portfolio in specialty pharma plus digital therapeutics provides durable competitive advantages: prescription-based revenue, clinical/regulatory barriers to entry, and licensing/partnership optionality. This business model supports recurring revenue and product-led growth over the medium term.
Bears Say
Steep Revenue ContractionA >50% TTM revenue decline undermines scale economics and the company’s ability to cover fixed costs. Over several months this can erode commercial positioning, weaken negotiating power with payers/partners, and make sustaining investments in pipeline or digital products more difficult without revenue recovery.
Persistent Negative ProfitabilityNegative gross, operating, and net margins indicate core operations are not covering costs, limiting internal capital generation. Continued losses reduce runway for strategic programs, increase dependence on external funding if cash flow weakens, and constrain ability to scale profitable growth.
Historic Balance Sheet Volatility And Falling FCF GrowthPrior periods of heavy leverage and negative equity show capital-structure fragility; meanwhile FCF has declined vs prior year (-36.2%). This combination raises risk that current improvements could reverse under stress, limiting long-term credibility of the recovery without sustained cash flow.
Orexo AB News
ORX FAQ
What was Orexo AB’s price range in the past 12 months?
Orexo AB lowest stock price was kr17.50 and its highest was kr43.40 in the past 12 months.
What is Orexo AB’s market cap?
Orexo AB’s market cap is kr722.88M.
When is Orexo AB’s upcoming earnings report date?
Orexo AB’s upcoming earnings report date is Jul 16, 2026 which is in 31 days.
How were Orexo AB’s earnings last quarter?
Orexo AB released its earnings results on Apr 28, 2026. The company reported -kr3 earnings per share for the quarter, missing the consensus estimate of N/A by -kr3.
Is Orexo AB overvalued?
According to Wall Street analysts Orexo AB’s price is currently Overvalued.
Does Orexo AB pay dividends?
Orexo AB does not currently pay dividends.
What is Orexo AB’s EPS estimate?
Orexo AB’s EPS estimate is -1.6.
How many shares outstanding does Orexo AB have?
Orexo AB has 35,127,056 shares outstanding.
What happened to Orexo AB’s price movement after its last earnings report?
Orexo AB reported an EPS of -kr3 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.112%.
Which hedge fund is a major shareholder of Orexo AB?
Currently, no hedge funds are holding shares in SE:ORX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Orexo AB
Orexo AB (publ) operates as a specialist pharmaceutical company, dedicated to the research, development, and commercialization of both traditional medications and cutting-edge digital therapeutics. Its reach extends across key markets, including the United States, Europe, and the United Kingdom. Its portfolio of currently available treatments includes Zubsolv, provided in tablet form, which assists in the management of opioid dependence; Abstral, which addresses breakthrough pain episodes experienced by cancer patients; and Edluar, prescribed for temporary insomnia. The company's robust development pipeline features several innovative compounds: OX124 and OX125, designed for naloxone and nalmefene rescue situations respectively; OX640, targeting acute allergic reactions; and OX338, a sublingual tablet formulation of ketorolac intended for moderate to severe pain relief. Additionally, Orexo is progressing the OX-MPI program, which aims to treat microvascular conditions linked to chronic inflammatory diseases. Complementing its pharmaceutical offerings, Orexo also provides digital therapies such as deprexis, for managing mild to severe depression; vorvida, addressing alcohol use disorder; and modia, tailored for opioid use disorder. Founded in 1994, Orexo AB (publ) maintains its headquarters in Uppsala, Sweden.
ORX Company Deck
ORX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicates a materially improved financial position driven by the successful sale of ZUBSOLV U.S., resulting in strong cash proceeds (SEK 814 million net) and a net cash position (SEK 429.2 million), while allowing a strategic refocus on the AmorphOX platform and prioritized R&D milestones (OX640 pivotal trial planned Q4, OX390 in‑vivo starting Q1, IZIPRY filing target Q3/2026). However, near-term challenges remain including weak continued-operations revenue (SEK 3.3 million), negative continued-ops EBITDA (SEK -70 million for Q4), impairments (MODIA SEK 22 million), outstanding DOJ investigation risk, bond covenant remediation/possible redemption, restructuring costs in 2026, and reliance on partnerships and BARDA funding to sustain and accelerate development. Overall, the positives from the transaction, cash position, meeting 2025 metrics, and clear strategic direction outweigh the operational and legal headwinds, positioning Orexo to focus on technology-driven R&D growth but with execution and financing risks to monitor.View all SE:ORX earnings summariesTechnical Analysis
AlzeCure Pharma AB
―
Klaria Pharma Holding AB
―
Nanexa AB
―
Enzymatica AB
―
Enorama Pharma AB
―
Options Prices
Currently, No data available
---